Related Experiment Videos
Drug-eluting stents for cardiovascular disorders
Juan F Granada1, Grzegorz L Kaluza, Albert Raizner
1The Methodist DeBakey Heart Center, Baylor College of Medicine, 6535 Fannin, Room FB 1034, Houston, TX 77030, USA.
Current Atherosclerosis Reports
|June 10, 2003
Summary
Drug-eluting stents significantly reduce restenosis after coronary procedures. These drug-eluting stents (DES) offer over 80% improvement compared to bare metal stents, potentially expanding treatment options.
Area of Science:
- Cardiovascular Medicine
- Biomedical Engineering
- Interventional Cardiology
Background:
- Restenosis remains a significant challenge after coronary artery implantation.
- Drug-eluting stents (DES) have been developed to address this issue.
- Bare metal stents (BMS) have limitations in preventing restenosis.
Purpose of the Study:
- To evaluate the efficacy of drug-eluting stents in preventing restenosis.
- To compare the performance of DES against BMS in clinical trials.
- To explore the potential of DES in expanding percutaneous coronary intervention eligibility.
Main Methods:
- Review of early randomized clinical trials.
- Analysis of drug elution from polymeric and nonpolymeric coatings.
- Comparison of restenosis rates between DES and BMS in simple de novo lesions.
Main Results:
- Drug-eluting stents demonstrated over 80% reduction in restenosis compared to bare metal stents.
- Paclitaxel and sirolimus eluted from stents showed significant efficacy.
- DES are effective in simple de novo coronary lesions.
Conclusions:
- Drug-eluting stents are a highly promising therapy for preventing restenosis.
- DES may enable percutaneous intervention for a broader range of patients and lesions.
- Stent-based therapies hold potential for treating atherosclerosis.